Montagu Private Equity (Montagu) has today signed an agreement
to acquire the 50/50 joint venture BSN medical, Hamburg, from its
parents Smith & Nephew plc London ("Smith & Nephew") and
Beiersdorf AG, Hamburg ("Beiersdorf") for € 1.030 billion. This
agreement is conditional upon competition clearances being
received. Final completion of the sale is expected in the first
quarter of 2006.
BSN medical is a leading global player in the professional medical
products market for general wound care, non-invasive orthopaedics
and phlebology. It was established in April 2001 to combine the
former casting and bandaging, general wound care and phlebology
business of Beiersdorf and Smith & Nephew. BSN medical has
manufacturing facilities in Germany, France, Ireland, Mexico,
Pakistan, South Africa, the UK, and the US. It operates in 25
countries, employs approx. 3,400 staff and is expecting revenues of
€ 525 million for 2005.
Denis Leroy, Head of European Investment at Montagu commented:
"This represents another exciting investment for Montagu; backing a
top quality business and first rate management team. The BSN
management has an impressive track record of developing the
business and improving margins over the last few years, and has
proven its ability to acquire and successfully integrate
strategically attractive companies. We look forward to supporting
the management team and employees in pursuing the growth strategy.
BSN medical is the first investment from our new fund, Montagu III,
which we closed in summer 2005 with EUR 2.3 billion"
Graham Siddle, CEO of BSN medical added: "Over the past four years
Smith & Nephew and Beiersdorf have supported us as we developed
becoming a major global leader in professional medical products.
This is just the start. With the support of Montagu we look forward
to realising the full potential of growth opportunities for BSN
medical. Our business portfolio is well suited for selective
bolt-on acquisitions and our existing distribution network will
benefit from new product launches in adjacent and existing
markets."
Back to top